Activity Summary:
As the treatment landscape for pulmonary arterial hypertension (PAH) continues to evolve, clinicians face increasingly complex decisions regarding therapy sequencing, route selection, titration, and treatment transitions. Long-term success depends not only on selecting an appropriate therapy, but also on managing treatment over time while balancing efficacy, tolerability, patient preferences, and treatment burden.

Through a series of focused, case-based mini-modules, this educational activity explores the practical realities of longitudinal PAH management. Participants will gain expert insights into strategies for optimizing therapy through appropriate sequencing, titration, escalation, and de-escalation decisions.

Activity Summary:
To further expand knowledge from From Diagnosis to Discontinuation: Rethinking the IPF Patient Experience, presented by Dr. Kevin R. Flaherty, HCPs can access a downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Clinical Slide Deck
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Join internationally recognized ILD experts Steven D. Nathan, MD, Kevin R. Flaherty, MD, and Ayodeji Adegunsoye, MD, MS, as they explore the latest advances transforming the diagnosis and management of fibrotic interstitial lung diseases (ILDs).

This interactive symposium combines expert insights, real-world cases, and live audience polling to help clinicians diagnose ILD earlier, recognize disease progression, optimize antifibrotic therapy, and apply emerging evidence to personalize patient care. Leave with practical strategies you can implement immediately to improve outcomes for patients with fibrotic ILD.care.

Can't attend in-person? We have a virtual option available!

Activity Summary:
Idiopathic pulmonary fibrosis (IPF) presents ongoing challenges across the patient journey, from timely diagnosis to long-term disease management. Nonspecific symptoms often delays appropriate imaging and referral, while issues related to antifibrotic tolerability and treatment discontinuation may further complicate care. Clinicians must also consider changes in physiologic measures, including DLco, alongside emerging understanding of pulmonary vascular involvement and evolving therapeutic approaches.

In this podcast, Dr. Kevin Flaherty shares expert perspectives and case-based insights on recognizing IPF earlier, optimizing antifibrotic therapy, proactively addressing adverse events, and interpreting key diagnostic and prognostic indicators. Listen in to explore strategies that can help inform timely diagnosis, individualized treatment decisions, and ongoing care for patients living with IPF.

Activity Summary:
Idiopathic pulmonary fibrosis (IPF) remains challenging to diagnose and manage in routine clinical practice. Nonspecific symptoms often delay HRCT imaging and referral, while real-world barriers such as antifibrotic tolerability and early discontinuation complicate long-term management. Clinicians must also interpret physiologic trends, including DLco decline, and integrate evolving insights into pulmonary vascular involvement and emerging therapies.

Throughout this video, Dr. Kevin Flaherty provides practical, case-based strategies to strengthen early recognition, optimize antifibrotic use, manage adverse events proactively, and interpret key diagnostic and prognostic markers. Through clinical scenarios and expert perspectives, participants will gain actionable tools to support earlier diagnosis, more personalized treatment decisions, and sustained care for patients with IPF.

Activity Summary:
To further expand knowledge from the What's New Doc? From Data to Decisions: Advancing IPF Care in 2026 presented by Dr. Steven Nathan, HCPs can access downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights
Concise, one-page summaries of key IPF studies featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

These resources are not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Advances in idiopathic pulmonary fibrosis (IPF) research continue to provide new insights into disease biology, treatment strategies, and the evolving evidence landscape. Yet, translating emerging data into clinical practice remains a challenge for many healthcare professionals.

In this podcast episode, Dr. Steven Nathan discusses the latest clinical trial findings, real-world evidence, and scientific developments shaping the current understanding of IPF. Through expert analysis and practical discussion, he explores the implications of these advances for disease management, treatment decision-making, and the future of IPF care in 2026.

Activity Summary:
Recent advances in idiopathic pulmonary fibrosis (IPF) continue to expand the evidence base, offering important insights into disease biology, therapeutic strategies, and ongoing research. However, clinicians often face challenges in interpreting and applying these insights within the context of evolving IPF care.

In this What's New Doc video, Dr. Steven Nathan reviews the latest clinical trial findings, real-world evidence, and scientific advances shaping the evolving understanding of IPF. By translating emerging data into practical clinical insights, he discusses their impact on disease management, treatment decisions, and the future direction of IPF care in 2026.

Activity Summary:
To further expand knowledge from the Clinical Clips® in PAH: Conference Highlights, presented by Dr. Vallerie McLaughlin, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Clinical Summary Resource
Concise, one-page summary highlighting the most clinically relevant PAH studies and late-breaking presentations discussed in the Clinical Clip.

Downloadable Slide Kit
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
To further expand knowledge from Echo's, Algorithms, and the Art of ILD-PH Detection presented by Dr. Steven Nathan, HCPs can access downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Downloadable Slides
Downloadable PDF presentation slides, including data, visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the video/podcast for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Despite progress in disease identification and treatment strategies, PAH continues to carry considerable morbidity and mortality, highlighting the need for continued optimization of disease management.

Throughout this educational podcast, Dr. Vallerie McLaughlin highlights the latest advances in PAH presented at the International 2026 Conference in Orlando, FL.

Activity Summary:
Despite advances in disease recognition and therapeutic options, PAH remains associated with significant morbidity and mortality, underscoring the importance of optimizing disease management.

Throughout this Clinical Clip, Dr. Vallerie McLaughlin reviews the study design, patient populations, clinical endpoints, efficacy outcomes, and safety findings of selected high-impact research presented in Orlando, Florida May 15-20 at the International 2026 Conference.

Activity Summary:
Pulmonary hypertension (PH) remains a serious and often underrecognized complication in patients with interstitial lung disease (ILD), significantly contributing to increased morbidity, mortality, and overall healthcare burden. Because of the clinical overlap between fibrotic lung disease and PH, early signs are frequently missed, leading to delays in diagnosis and limited opportunities for timely intervention. Evolving definitions and diagnostic criteria for PH further highlight the need to refine and update current screening approaches—especially for patients with early or borderline disease.

In this expert-led podcast, Dr. Nathan shares practical insights on recognizing early indicators of PH in the setting of ILD, interpreting key diagnostic findings, and applying effective risk stratification strategies. The discussion focuses on improving early detection and optimizing management to ultimately enhance outcomes for this high-risk patient population.

Activity Summary:
PH is a serious and frequently underdiagnosed complication in patients with ILD, contributing to increased morbidity, mortality, and healthcare burden. The clinical overlap between fibrotic lung disease and PH often results in delayed recognition and missed opportunities for early intervention. Recent updates to PH definitions and diagnostic criteria underscore the importance of revising clinical screening strategies, particularly for patients with borderline or early-stage disease.

During this expert led video, Dr. Nathan presents key insights on identifying early signs of PH in ILD, interpreting relevant diagnostic data, and appropriately stratifying risk – aiming to improve diagnosis, management, and outcomes in this high-risk population.

Activity Summary:
To further expand knowledge from the What's New Doc? End-of-the-Year Updates on IPF presented by Dr. Steven Nathan, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights
Concise, one-page summaries of key IPF studies featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Despite advances in understanding PAH, several opportunities remain to further improve patient outcomes, particularly in timely diagnosis, the differentiation to other PH subtypes, treatment challenges, and the management of cardiovascular comorbidities.

During these two Clinical Snippet episodes, Dr. Oudiz highlights the latest advances in PAH that were presented at fall conferences in Seattle, WA; Chicago, IL; and Amsterdam, Netherlands in September-October 2025.

Activity Summary:
PH is currently divided into groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This educational slide kit presents the latest research in diagnosing and managing Group 2-5 in patients, including the distinction of specific groups – CTEPH, PH-ILD, PH-COPD, CPFE, CTD.

Activity Summary:
New analyses show rising prevalence of progressive pulmonary fibrosis, persistent diagnostic delays, and continued gaps in antifibrotic use. Fresh data from major trials, including nerandomilast, inhaled treprostinil, admilparant, deupirfenidone, and nalbuphine ER for chronic cough, point to meaningful advances on the horizon. At the same time, patient-centered research highlights the need for clearer communication, coordinated care, and earlier intervention to improve daily functioning and long-term outcomes.

This CME activity brings all these findings together in one clear, concise program that helps clinicians keep pace with a rapidly changing field and deliver more effective, patient-focused care.

Activity Summary:
IPF care is shifting fast, and this year brought major data that will influence how clinicians diagnose, monitor, and manage disease in the year ahead. What’s New Doc? End-Of-The-Year Updates on IPF is a focused, high-impact CME activity designed to give pulmonologists, ILD specialists, and multidisciplinary care teams a clear view of the most important 2025 findings and how they translate to practice.

This activity reviews new epidemiologic insights, real-world antifibrotic outcomes, patient-reported challenges, and the latest trial results for emerging therapies expected to shape care in 2026. Steven Nathan, MD guides learners through the evidence with practical takeaways that support better decision making on diagnosis, therapy selection, tolerability management, and quality-of-life improvement.

Activity Summary:
Methamphetamine use is a growing public health concern with serious cardiovascular consequences. One of the most challenging and underrecognized complications is methamphetamine-associated pulmonary arterial hypertension (Meth-APAH), a progressive condition with high morbidity that often presents alongside complex psychosocial and adherence issues.

This on-demand, case-based CME activity equips clinicians with the knowledge and tools to identify, evaluate, and manage Meth-APAH using an evidence-based, multidisciplinary approach.

Activity Summary:
To reinforce key insights from the Transforming ILD Management activity and support real-world application, this resource library offers downloadable materials for quick reference and team-based learning. Designed for busy clinicians, these tools include concise visual summaries, clinical takeaways, and ready-to-share content that complement the podcast and highlights video.

Available Resources:

• Clinical Snippet Highlights
  Concise, one-page summaries of key ILD posters and abstracts presented in Chicago, IL, from October 19-22, 2025, featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.
• Interactive Q&A Summaries
  Concise summaries of expert faculty responses to key questions on ILD diagnosis and management, compiled for easy reference after the program.
• Guideline Updates
  A summary of the latest update to ILD-related guidelines to support evidence-based practice.
• References and Resource Links
  Direct access to featured studies, abstracts, and other key materials cited in the program.
• Accredited Slides
  Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.
• Expert Commentary Transcript
  A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:

COPD care is evolving - are you keeping up? In this four-part podcast series, Drs. Sonali Bose and MeiLan Han share practical insights on personalizing COPD treatment, applying the latest guideline updates, and managing complex cases of dyspnea and exacerbation. Through expert discussion and case-based learning, you’ll gain strategies to confidently navigate therapeutic decision-making and improve patient outcomes.

What You’ll Learn:

• How to apply 2025 GOLD guideline updates to your COPD practice
• Strategies for managing patients with persistent symptoms despite dual or triple therapy
• Biomarker-driven decision-making for recurrent exacerbations
• Real-world case reviews with actionable, expert commentary

Activity Summary:
Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical findings in COPD Management. This activity includes four modules:

1. COPD Management
2. Highlights from 2025 Conferences and Publications
3. Persistent Dyspnea Despite Guideline-based Therapy (Case Review)
4. Recurrent Exacerbations in Biomarker-defined Subgroup (Case Review)